Results 201-220 of 333 for 5 million speaker:Simon Harris
- Written Answers — Department of Health: Medicinal Products Availability (13 Feb 2018)
Simon Harris: I propose to take Questions Nos. 356, 364, 396 and 405 together. Medicines play a vital role in improving the health of Irish patients. Securing access to existing and new and innovative medicines is a key objective of the health service. However, the challenge is to do this in an affordable and sustainable manner. The medicines bill for the community drugs schemes – primarily the...
- Written Answers — Department of Health: Medicinal Products (13 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Reimbursement (13 Feb 2018)
Simon Harris: I propose to take Questions Nos. 443 and 451 together. Medicines play a vital role in improving the health of Irish patients. Securing access to existing and new and innovative medicines is a key objective of the health service. However, the challenge is to do this in an affordable and sustainable manner. The medicines bill for the community drugs schemes – primarily the GMS, Long...
- Written Answers — Department of Health: Medicinal Products Reimbursement (8 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medical Card Drugs Availability (6 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Drugs Payment Scheme (6 Feb 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Reimbursement (31 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medical Aids and Appliances Provision (31 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Drugs Payment Scheme Coverage (30 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Drugs Payment Scheme Coverage (30 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Supply (25 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Reimbursement (24 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Medicinal Products Availability (18 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Hospital Trolley Crisis: Motion [Private Members] (16 Jan 2018)
Simon Harris: ...committed to investing in health and investment is having an impact. We do not often hear this but some things are going well in the health service. This year, as part of budget 2018, an extra €30 million was made available to respond to winter pressures, with a further €40 million being provided in 2018. Let me share something that Deputies may not have heard this winter....
- Written Answers — Department of Health: Drugs Payment Scheme Coverage (16 Jan 2018)
Simon Harris: ...Centre for Pharmacoeconomics (NCPE). The NCPE Health Technology Assessment was completed in July 2017 estimated on the basis of the price originally proposed that a budget of in excess of €65 million over 5 years would have been required to support reimbursement of palbociclib(Ibrance). They did not recommend reimbursement. The HSE has engaged with the company in question in...
- Written Answers — Department of Health: Medical Products (16 Jan 2018)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: General Medical Services Scheme (14 Dec 2017)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Written Answers — Department of Health: Drugs Payment Scheme Coverage (13 Dec 2017)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic neuralgia (PHN), in...
- Health Insurance (Amendment) Bill 2017 [Seanad]: Second Stage (30 Nov 2017)
Simon Harris: ...tries to ensure equity and fairness, which I believe is reflected by a societal belief that is held across the State. The number of people who currently hold private health insurance is more than 2.1 million, with three commercial insurers operating within the market. There is, however, a clear disparity in the membership profile and thus the associated costs being incurred across the...
- Written Answers — Department of Health: Medical Card Drugs Availability (29 Nov 2017)
Simon Harris: ...and effectively. This requires an integrated approach to secure best value for money for all treatments, greater efficiencies in the supply chain and the use of the most cost-effective treatments. Lidocaine 5% medicated plaster (Versatis) is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection, known as post-herpetic...